MMP2 and non-small cell lung carcinoma: In agreement with these and other previous studies, our results showed that gefitinib-treated NSCLC cells with MET amplification display a significant reduction in both MMP-2 and MMP-9 proteolytic activity associated with reduced phosphorylation of p38 MAPK.